Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: A 15-year follow-up study

Multiple Sclerosis

Volumn 16, Issue 5, 2010, Pages 588-596

  Bermel, R A ^a   Weinstock Guttman, B ^b   Bourdette, D ^c   Foulds, P ^d   You, X ^d   Rudick, R A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b JACOBS NEUROLOGICAL INSTITUTE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d BIOGEN   (United States)

Author keywords

Disease modifying therapy; EDSS; Interferon beta 1a; Long term; Multiple sclerosis; Quality of life; SF 36

Indexed keywords

AZATHIOPRINE; BEE VENOM; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; GLATIRAMER; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; STEROID;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISABILITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; QUALITY OF LIFE; SELF CARE; SHORT FORM 36; VISUAL ANALOG SCALE;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 77952796371     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509360549     Document Type: Article

References (26)

1. Kappos L., Freedman MS, Polman CH, et al. Effect of early versus delayed interferon β-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a three-year follow-up analysis of the BENEFIT study. Lancet 2007 ; 370: 389-396.
2. Kinkel RP Interferon-β1a: a once-weekly immunomodulatory treatment for patients with multiple sclerosis. Expert Rev Clin Immunol 2006 ; 2: 691-704.
3. Lutterotti A., Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol 2008 ; 7: 538-547.
4. Confavreux C., Vukusic S., Moreau T., Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000 ; 343: 1430-1438.
5. Weinshenker BG, Bass B., Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study I. Clinical course and disability. Brain 1989 ; 112: 133-146. (Pubitemid 19056478)
6. Tremlett H., Paty D., Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006 ; 66: 172-177.
7. Rudick RA, Miller DM Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment. CNS Drugs 2008 ; 22: 827-839.
8. The Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: part II: quality of life. Can J Neurol Sci 1998 ; 25: 31-38.
9. Rudick RA, Miller D., Clough JD, Gragg LA, Farmer RG Quality of life in multiple sclerosis: comparison with inflammatory bowel disease and rheumatoid arthritis. Arch Neurol 1992 ; 49: 1237-1242.
10. Riazi A., Hobart JC, Lamping DL, et al. Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinsons disease with normal population health profiles. J Neurol Neurosurg Psychiatry 2003 ; 74: 710-714.
11. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996 ; 39: 285-294.
12. Rudick RA, Cutter GR, Baier M., et al. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. Mult Scler 2005 ; 11: 626-634.
13. Rudick RA, Cutter G., Baier M., et al. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology 2001 ; 56: 1324-1330. (Pubitemid 32455292)
14. Fisher E., Rudick RA, Cutter G., et al. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 2000 ; 6: 373-377.
15. Marrie RA, Fisher E., Miller DM, Lee JC, Rudick RA Association of fatigue and brain atrophy in multiple sclerosis. J Neurol Sci 2005 ; 228: 161-166.
16. Miller DM, Rudick RA, Baier M., et al. Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis. Mult Scler 2003 ; 9: 1-5.
17. Fisher E., Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002 ; 59: 1412-1420.
18. Ware JE, Sherbourne CD The MOS 36-item Short Form Health Survey: conceptual framework and item selection. Med Care 1992 ; 30: 473-483.
19. Rudick RA, Miller D., Hass S., et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007 ; 62: 335-346. (Pubitemid 350105948)
20. Ratzker PK, Feldman JM, Scheinberg LC, et al. Self-assessment of neurologic impairment in multiple sclerosis. J Neuro Rehab 1997 ; 11: 207-211.
21. Rudick RA, Cutter G. Interferon-beta for multiple sclerosis: long-term benefits? Ann Neurol 2007 ; 61: 283-285.
22. The IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993 ; 43: 655-661.
23. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a double-blind, placebo-controlled trial. Neurology 1995 ; 45: 1268-1276.
24. PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/ remitting multiple sclerosis. Lancet 1998 ; 352: 1498-1504.
25. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000 ; 343: 898-904.
26. Comi G., Filippi M., Barkhof F., et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 2001 ; 357: 1576-1582.